BioRestorative Therapies Inc (BRTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioRestorative Therapies Inc (BRTX) has a cash flow conversion efficiency ratio of -1.315x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.90 Million) by net assets ($2.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioRestorative Therapies Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how BioRestorative Therapies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BRTX liabilities breakdown for a breakdown of total debt and financial obligations.
BioRestorative Therapies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioRestorative Therapies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greenwave Technology Solutions Inc. Common Stock
NASDAQ:GWAV
|
-0.100x |
|
Keystone Law Group PLC
LSE:KEYS
|
0.375x |
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
-0.380x |
|
Korab Resources Ltd
AU:KOR
|
-0.163x |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
-0.078x |
|
Baillie Gifford China Growth Trust PLC
LSE:BGCG
|
-0.002x |
|
Enveric Biosciences Inc
NASDAQ:ENVB
|
-0.600x |
|
Fonix Mobile plc
LSE:FNX
|
0.339x |
Annual Cash Flow Conversion Efficiency for BioRestorative Therapies Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of BioRestorative Therapies Inc from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see BRTX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.53 Million | $-8.23 Million | -0.965x | -50.09% |
| 2023-12-31 | $10.00 Million | $-6.43 Million | -0.643x | -11.85% |
| 2022-12-31 | $10.29 Million | $-5.91 Million | -0.575x | -272.69% |
| 2021-12-31 | $21.60 Million | $-3.33 Million | -0.154x | -110.45% |
| 2020-12-31 | $-1.33 Million | $-1.96 Million | 1.475x | +172.42% |
| 2019-12-31 | $-12.78 Million | $-6.92 Million | 0.542x | -8.33% |
| 2018-12-31 | $-8.64 Million | $-5.10 Million | 0.591x | +4.80% |
| 2017-12-31 | $-6.84 Million | $-3.85 Million | 0.564x | -43.66% |
| 2016-12-31 | $-5.00 Million | $-5.00 Million | 1.000x | +25.25% |
| 2015-12-31 | $-3.91 Million | $-3.12 Million | 0.799x | +70.47% |
| 2014-12-31 | $-6.89 Million | $-3.23 Million | 0.469x | +17.22% |
| 2013-12-31 | $-6.69 Million | $-2.67 Million | 0.400x | -35.45% |
| 2012-12-31 | $-5.14 Million | $-3.18 Million | 0.619x | -18.78% |
| 2011-12-31 | $-3.69 Million | $-2.81 Million | 0.762x | -22.18% |
| 2010-12-31 | $-744.22K | $-729.22K | 0.980x | -- |
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more